KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Pulmonary Hypertension in Interstitial Lung Disease: Management Options to Move Beyond Supportive Care.

Kimberly D Fabyan, Abhimanyu Chandel, Christopher S King

Curr Pulmonol Rep 1-8

PMID37362782
PMCIDPMC10200699
DOI10.1007/s13665-023-00311-2
发表日期2023-06-26
摘要

摘要

PURPOSE OF REVIEW: This review delineates current diagnostic and management strategies for pulmonary hypertension due to interstitial lung disease (PH-ILD). RECENT FINDINGS: The INCREASE trial, a phase III multicenter, randomized, placebo-controlled trial demonstrated both improved 6-min walk distance and decreased disease progression with inhaled treprostinil. This pivotal trial led to inhaled treprostinil becoming the first FDA approved medication for treatment of PH-ILD. The availability of this treatment has generated subsequent recommendations for the screening for PH in patients with ILD. As a result, it is becoming increasingly important for clinicians to gain awareness and familiarity with the evolving management options for PH-ILD. SUMMARY: The management of PH-ILD has its roots in goal-directed treatment of the underlying lung disease. However, recent medication advances and ongoing clinical studies are opening opportunities for more disease-specific treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。